Literature DB >> 24781441

Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.

Holland C Detke1, Peter J Weiden, Pierre-Michel Llorca, Moutaz Choukour, Susan B Watson, Elizabeth Brunner, Haya Ascher-Svanum.   

Abstract

We compared long-term treatment effectiveness of monthly olanzapine long-acting injection (LAI) with that of oral olanzapine. Outpatients with 2 or more episodes of psychotic worsening in the past 24 months with Positive and Negative Syndrome Scale total score of lower than 70 were randomized to 405 mg/4 weeks of olanzapine LAI (n = 264) or 10 mg/d of oral olanzapine (n = 260) for 2 years of open-label treatment. Dosing thereafter was flexible (150-405 mg/4 weeks of LAI vs 5-20 mg/d of oral). Primary outcome was time to all-cause discontinuation. At baseline, patients were clinically stable (mean Positive and Negative Syndrome Scale total score of 57). Seventeen percent of patients had been psychiatrically hospitalized in the previous 6 months, and 4.6% were rated nonadherent in the month before study entry. The groups did not differ significantly in median time to all-cause discontinuation (645 days for LAI, 678 days for oral; P = 0.61), discontinuation rate (53.8% for LAI, 51.2% for oral; P = 0.60), or relapse rate (20.1% for LAI, 18.5% for oral; P = 0.66). Postbaseline psychiatric hospitalization rate was low for both groups (7.6% for LAI, 9.2% for oral), but mean hospitalization duration was significantly longer for oral patients (1.80 days [20 for those hospitalized] vs 0.43 days [6 for those hospitalized], P = 0.02). There were no clinically significant group differences in adverse events or safety measures. No post-injection delirium/sedation syndrome events occurred. In conclusion, olanzapine LAI and oral olanzapine were similarly effective and well tolerated for up to 2 years of treatment in patients with schizophrenia. Treatment discontinuation for olanzapine LAI was similar to that of oral olanzapine, despite the 3-hour post-injection observation period and other precautionary procedures related to risk of post-injection delirium/sedation syndrome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24781441     DOI: 10.1097/JCP.0000000000000140

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.

Authors:  Daniel Luedecke; Daniel Schöttle; Anne Karow; Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 2.  Practical clinical trials in psychopharmacology: a systematic review.

Authors:  Benedetto Vitiello
Journal:  J Clin Psychopharmacol       Date:  2015-04       Impact factor: 3.153

3.  Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

Authors:  Giovanni Ostuzzi; Federico Bertolini; Federico Tedeschi; Giovanni Vita; Paolo Brambilla; Lorenzo Del Fabro; Chiara Gastaldon; Davide Papola; Marianna Purgato; Guido Nosari; Cinzia Del Giovane; Christoph U Correll; Corrado Barbui
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

4.  Updating the Comparative Evidence on Second-Generation Antipsychotic Use With Schizophrenia.

Authors:  Marian S McDonagh; Tracy Dana; Shelley Selph; Emily B Devine; Amy Cantor; Christina Bougatsos; Ian Blazina; Sara Grusing; Rongwei Fu; Daniel W Haupt
Journal:  Psychiatr Res Clin Pract       Date:  2020-10-16

5.  Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.

Authors:  David P McDonnell; John Landry; Holland C Detke
Journal:  Int Clin Psychopharmacol       Date:  2014-11       Impact factor: 1.659

Review 6.  Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Seon-Cheol Park; Mi Young Choi; Jina Choi; Eunjung Park; Ha Jin Tchoe; Jae Kyung Suh; Young Hoon Kim; Seung Hee Won; Young-Chul Chung; Kyung-Yeol Bae; Sang-Kyu Lee; Chan Mi Park; Seung-Hwan Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

7.  Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary.

Authors:  P Takács; P Czobor; L Fehér; J Gimesi-Országh; P Fadgyas-Freyler; M Bacskai; P Rakonczai; A Borsi; R Hegyi; T Németh; J Sermon; I Bitter
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

8.  Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jordan Bertsch; David McDonnell; Holland Detke
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-20       Impact factor: 2.570

9.  Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.

Authors:  Holland C Detke; John Lauriello; John Landry; David P McDonnell
Journal:  Int J Methods Psychiatr Res       Date:  2014-07-03       Impact factor: 4.035

10.  Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics.

Authors:  Chelsea N Carr; Colleen P Hall; Jennifer E Roche-Desilets; Christopher J Burant; Matthew A Fuller
Journal:  Ment Health Clin       Date:  2016-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.